NCT03234036 - A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 2, 2017

Primary Completion Date

November 10, 2017

Study Completion Date

November 10, 2017

Conditions

Infection, Human Immunodeficiency VirusHIV Infections

Interventions

DRUG

GSK2838232 100 mg tablet

It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.

DRUG

GSK2838232 50 mg capsule

It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.

DRUG

Ritonavir 100 mg tablets

It is a white film-coated ovaloid tablets.

DRUG

Placebo for GSK2838232 tablets

It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.

Trial Locations (1)

21225

GSK Investigational Site, Baltimore